Bullish launches Bitcoin benchmark tool for ETFs and index funds
Bullish has introduced the Bullish Closing Cross, the first daily closing auction for spot Bitcoin offered by an NYSE-listed digital asset platform. The service aims to establish a deterministic daily closing price for BTC/USDC, supporting institutional investors, ETFs, and index funds that require reliable valuation benchmarks.
Held each day at 4:00 p.m. Eastern Time, the auction concentrates global trading interest into a single liquidity event, with order imbalance data published before execution. Simultaneous USD/USDC and USDT/USD auctions will also allow participants to manage currency conversions within the same process.
According to Bullish, the Closing Cross introduces an equity-style closing auction to Bitcoin markets, creating a transparent benchmark that can enhance price discovery, fund valuation, index rebalancing, and institutional trading workflows.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The "Outlier" Investment Art in the New Era of Berky
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India
Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge
The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales
Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.
Crypto prices
More
